Across TCGA pan-cancer cohorts, RPL32P22 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL32P22’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RPL32P22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL32P22 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

LIHC, BRCA, and PAAD are the cancer types where RPL32P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL32P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.094	<.001	4	view →
BRCA	Female	All	−0.123	.021	3	view →
PAAD	Male	All	+0.290	.018	2	view →
COAD	All	II,III,IV	+0.172	.026	2	view →
LUSC	All	All	+0.131	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL32P22 RNA expression & survival · all RPL32P22 data types